These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842 [TBL] [Abstract][Full Text] [Related]
3. Vincaleukoblastine. NOBLE RL Can Med Assoc J; 1961 Sep; 85(10):610-1. PubMed ID: 13729372 [No Abstract] [Full Text] [Related]
4. Vincaleukoblastine (solid tumors). MOORE GE; WATNE AL Cancer Chemother Rep; 1961 Jun; 12():192-7. PubMed ID: 13772297 [No Abstract] [Full Text] [Related]
5. Vincaleukoblastine. III. Clinical trial with the oral preparation. HODES ME; ROHN RJ; BOND WH; YARDLEY J Cancer Chemother Rep; 1961 Oct; 14():129-38. PubMed ID: 13907937 [No Abstract] [Full Text] [Related]
6. Vincaleukoblastine in the treatment of malignant disease. WHITELAW DM; TEASDALE JM Can Med Assoc J; 1961 Sep; 85(10):584-91. PubMed ID: 13784890 [No Abstract] [Full Text] [Related]
7. [Clinical experiences with vincaleukoblastine (Velbe), a new cytostatic]. KEISER G; BRUNNER K; MARTZ G Schweiz Med Wochenschr; 1962 Apr; 92():486-93. PubMed ID: 14454863 [No Abstract] [Full Text] [Related]
8. Vincaleukoblastine. I. Preliminary clinical studies. HODES ME; ROHN RJ; BOND WH Cancer Res; 1960 Aug; 20():1041-9. PubMed ID: 14402218 [No Abstract] [Full Text] [Related]
9. Vincaleukoblastine. IV. A summary of two and one-half years' experience in the use of vinblastine. HODES ME; ROHNRJ ; BOND WH; YARDLEY JM; CORPENING WS Cancer Chemother Rep; 1962 Feb; 16():401-6. PubMed ID: 13907938 [No Abstract] [Full Text] [Related]
10. Some biological effects of Vincaleukoblastine, an alkaloid in Vinca rosea Linn in patients with malignant disease. WARWICK OH; DARTE JM; BROWN TC; BEER CT; CUTTS JH; NOBLE RL Cancer Res; 1960 Aug; 20():1032-40. PubMed ID: 13842983 [No Abstract] [Full Text] [Related]
11. Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine. JOHNSON IS; WRIGHT HF; SVOBODA GH; VLANTIS J Cancer Res; 1960 Aug; 20():1016-22. PubMed ID: 14407465 [No Abstract] [Full Text] [Related]
12. The effect of vincaleukoblastine on primary cultures of human neoplasms. A preliminary report. WALKER DG; WRIGHT JC Cancer Chemother Rep; 1961 Oct; 14():139-44. PubMed ID: 14004574 [No Abstract] [Full Text] [Related]
13. Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. CUTTS JH; BEER CT; NOBLE RL Cancer Res; 1960 Aug; 20():1023-31. PubMed ID: 13719013 [No Abstract] [Full Text] [Related]
14. The stathmokinetic effect of vincaleukoblastine on normal bone marrow and leukemic cells. CARDINALI G; CARDINALI G; BLAIR J Cancer Res; 1961 Dec; 21():1542-4. PubMed ID: 13876510 [No Abstract] [Full Text] [Related]
15. Effect of Vincaleukoblastine on metastatic choriocarcinoma and related trophoblastic tumors in women. HERTZ R; LIPSETT MB; MOY RH Cancer Res; 1960 Aug; 20():1050-3. PubMed ID: 13713829 [No Abstract] [Full Text] [Related]
16. [Adjuvant chemotherapy in surgery of cancer. Malignant dysembryoma of the testicle with multiple metastases; temporary success of vincaleukoblastine]. JALLUT O; PETTAVEL J Helv Chir Acta; 1963 Apr; 30():125-35. PubMed ID: 13957219 [No Abstract] [Full Text] [Related]
17. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Lin AM; Ryan CJ; Small EJ Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610 [TBL] [Abstract][Full Text] [Related]
18. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy. Amikura T; Aoki Y; Kase H; Watanabe M; Sato T; Fujita K; Kurata H; Tanaka K Int J Clin Oncol; 2002 Feb; 7(1):45-50. PubMed ID: 11942049 [TBL] [Abstract][Full Text] [Related]
19. [Therapy of lymphogranulomatosis with Vincaleukoblastine]. STECHER G Folia Haematol (Frankf); 1963 Apr; 7():19-21. PubMed ID: 13983552 [No Abstract] [Full Text] [Related]
20. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]